NL8802007A - Vaccin, geschikt voor de profylaxe respectievelijk de bestrijding van de door haemophilus pleuropneumoniae teweeggebrachte ziekte bij varkens alsmede werkwijze voor het winnen van extracellulair eiwitachtig materiaal van haemophilus pleuropneumonie, geschikt voor toepassing in dergelijke vaccins. - Google Patents
Vaccin, geschikt voor de profylaxe respectievelijk de bestrijding van de door haemophilus pleuropneumoniae teweeggebrachte ziekte bij varkens alsmede werkwijze voor het winnen van extracellulair eiwitachtig materiaal van haemophilus pleuropneumonie, geschikt voor toepassing in dergelijke vaccins. Download PDFInfo
- Publication number
- NL8802007A NL8802007A NL8802007A NL8802007A NL8802007A NL 8802007 A NL8802007 A NL 8802007A NL 8802007 A NL8802007 A NL 8802007A NL 8802007 A NL8802007 A NL 8802007A NL 8802007 A NL8802007 A NL 8802007A
- Authority
- NL
- Netherlands
- Prior art keywords
- pleuropneumoniae
- pigs
- strain
- vaccine
- proteinaceous material
- Prior art date
Links
- 241000282887 Suidae Species 0.000 title claims description 42
- 229960005486 vaccine Drugs 0.000 title claims description 27
- 238000000034 method Methods 0.000 title claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 7
- 201000010099 disease Diseases 0.000 title description 5
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 claims description 52
- 239000000047 product Substances 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 20
- 206010035664 Pneumonia Diseases 0.000 claims description 16
- 239000001963 growth medium Substances 0.000 claims description 16
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 14
- 239000002953 phosphate buffered saline Substances 0.000 claims description 14
- 210000002966 serum Anatomy 0.000 claims description 13
- 241000204031 Mycoplasma Species 0.000 claims description 10
- 201000006509 pleuropneumonia Diseases 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 9
- 239000002609 medium Substances 0.000 claims description 9
- 239000002244 precipitate Substances 0.000 claims description 7
- 238000011321 prophylaxis Methods 0.000 claims description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 238000011146 sterile filtration Methods 0.000 claims description 5
- 244000052616 bacterial pathogen Species 0.000 claims description 4
- 241000606790 Haemophilus Species 0.000 claims description 3
- 238000011534 incubation Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 2
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 229960002715 nicotine Drugs 0.000 claims description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000003053 toxin Substances 0.000 description 10
- 231100000765 toxin Toxicity 0.000 description 10
- 108700012359 toxins Proteins 0.000 description 10
- 108010006464 Hemolysin Proteins Proteins 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 239000003228 hemolysin Substances 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 238000011081 inoculation Methods 0.000 description 8
- 241001494479 Pecora Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 101710112752 Cytotoxin Proteins 0.000 description 5
- 231100000599 cytotoxic agent Toxicity 0.000 description 5
- 239000002619 cytotoxin Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000006161 blood agar Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 230000002956 necrotizing effect Effects 0.000 description 2
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 208000032923 Lobar pneumonia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 210000004237 neck muscle Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 208000024356 pleural disease Diseases 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000006150 trypticase soy agar Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8802007A NL8802007A (nl) | 1988-08-12 | 1988-08-12 | Vaccin, geschikt voor de profylaxe respectievelijk de bestrijding van de door haemophilus pleuropneumoniae teweeggebrachte ziekte bij varkens alsmede werkwijze voor het winnen van extracellulair eiwitachtig materiaal van haemophilus pleuropneumonie, geschikt voor toepassing in dergelijke vaccins. |
| CA000607962A CA1334388C (en) | 1988-08-12 | 1989-08-10 | Vaccine suitable for prophylaxis and control, respectively, of the pig disease caused by haemophilus pleuropneumoniae as well as a method for obtaining extracellular proteinaceuosmaterial of haemophilus pleuropneumoniae suitable for use in such vaccines |
| AR89314639A AR243385A1 (es) | 1988-08-12 | 1989-08-11 | Metodo para la preparacion de una vacuna universal apropiada para la profilaxis y control del haemophilus pleuropneumoniae en cerdos. |
| EP89202080A EP0354628B1 (de) | 1988-08-12 | 1989-08-11 | Impfstoff, geeignet zur Verhütung bzw. Kontrolle der durch Haemophilus pleuropneumoniae verursachte Schweinekrankheit und Verfahren zu dessen Herstellung |
| AT89202080T ATE103816T1 (de) | 1988-08-12 | 1989-08-11 | Impfstoff, geeignet zur verhuetung bzw. kontrolle der durch haemophilus pleuropneumoniae verursachte schweinekrankheit und verfahren zu dessen herstellung. |
| DK394889A DK394889A (da) | 1988-08-12 | 1989-08-11 | Vaccine til profylakse og kontrol af haemophilus pleuropneumoniae i svin samt fremgangsmaade til fremstilling af extracellulaert proteinmateriale fra h. pleuropneumoniae til anvendelse i saadanne vacciner |
| US07/392,781 US5254340A (en) | 1988-08-12 | 1989-08-11 | Vaccine suitable for prophylaxis and control, respectively, of the pig disease caused by Haemophilus pleuropneumoniae and a method for obtaining extracellular proteinaceous material of Haemophilus pleuropneumoniae for use in such vaccines |
| JP1209519A JPH0725697B2 (ja) | 1988-08-12 | 1989-08-11 | ワクチンおよび方法 |
| DE68914362T DE68914362T2 (de) | 1988-08-12 | 1989-08-11 | Impfstoff, geeignet zur Verhütung bzw. Kontrolle der durch Haemophilus pleuropneumoniae verursachte Schweinekrankheit und Verfahren zu dessen Herstellung. |
| ES89202080T ES2055010T3 (es) | 1988-08-12 | 1989-08-11 | Vacuna adecuada para la profilaxis y el control, respectivamente, de la enfermedad del ganado porcino causada por haemophilus pleuropneumoniae y su metodo de obtencion. |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL8802007A NL8802007A (nl) | 1988-08-12 | 1988-08-12 | Vaccin, geschikt voor de profylaxe respectievelijk de bestrijding van de door haemophilus pleuropneumoniae teweeggebrachte ziekte bij varkens alsmede werkwijze voor het winnen van extracellulair eiwitachtig materiaal van haemophilus pleuropneumonie, geschikt voor toepassing in dergelijke vaccins. |
| NL8802007 | 1988-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8802007A true NL8802007A (nl) | 1990-03-01 |
Family
ID=19852751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8802007A NL8802007A (nl) | 1988-08-12 | 1988-08-12 | Vaccin, geschikt voor de profylaxe respectievelijk de bestrijding van de door haemophilus pleuropneumoniae teweeggebrachte ziekte bij varkens alsmede werkwijze voor het winnen van extracellulair eiwitachtig materiaal van haemophilus pleuropneumonie, geschikt voor toepassing in dergelijke vaccins. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5254340A (de) |
| EP (1) | EP0354628B1 (de) |
| JP (1) | JPH0725697B2 (de) |
| AR (1) | AR243385A1 (de) |
| AT (1) | ATE103816T1 (de) |
| CA (1) | CA1334388C (de) |
| DE (1) | DE68914362T2 (de) |
| DK (1) | DK394889A (de) |
| ES (1) | ES2055010T3 (de) |
| NL (1) | NL8802007A (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641653A (en) * | 1989-10-31 | 1997-06-24 | The Texas A&M University System | DNA encoding Actinobacillus pleuropneumoniae hemolysin |
| EP0453024B1 (de) * | 1990-04-20 | 1995-05-31 | Akzo Nobel N.V. | Untereinheit-Impfstoff gegen Actinobacillus Pleuropneumoniae |
| KR100258772B1 (ko) * | 1990-12-19 | 2000-08-01 | 피터씨.리챠드슨 | 돼지의 흉막폐염 백신 조성물 |
| US5994525A (en) * | 1991-06-28 | 1999-11-30 | Kamp; Elbarte Margriet | Nucleic acid encoding Actinobacillus pleuropneumoniae cytolytic proteins |
| JPH05262666A (ja) * | 1992-03-24 | 1993-10-12 | Biseibutsu Kagaku Kenkyusho:Kk | 豚胸膜肺炎多価ワクチン |
| US7008790B1 (en) * | 1993-08-12 | 2006-03-07 | Classen Immunotherapies, Inc. | Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae |
| US5728385A (en) * | 1993-08-12 | 1998-03-17 | Classen Immunotherapies, Inc. | Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae |
| US5925354A (en) | 1995-11-30 | 1999-07-20 | Michigan State University | Riboflavin mutants as vaccines against Actinobacillus pleuropneumoniae |
| CN116350641B (zh) * | 2023-02-07 | 2024-09-24 | 湖北省农业科学院畜牧兽医研究所 | 桧木醇与磺胺异恶唑组合物及其在抑制细菌中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK138379A (da) * | 1979-04-04 | 1980-10-05 | Nordisk Droge & Kemikalie | Vaccine imod pleuropneumonia (ondartet lungesyge) hos svin dens anvendelse samt fremgangsmaade og substat til dyrkning specielt aerob fermentering af mikroorganismen haemophilus pleuropneumoniae |
-
1988
- 1988-08-12 NL NL8802007A patent/NL8802007A/nl not_active Application Discontinuation
-
1989
- 1989-08-10 CA CA000607962A patent/CA1334388C/en not_active Expired - Fee Related
- 1989-08-11 ES ES89202080T patent/ES2055010T3/es not_active Expired - Lifetime
- 1989-08-11 DE DE68914362T patent/DE68914362T2/de not_active Revoked
- 1989-08-11 JP JP1209519A patent/JPH0725697B2/ja not_active Expired - Fee Related
- 1989-08-11 AT AT89202080T patent/ATE103816T1/de not_active IP Right Cessation
- 1989-08-11 AR AR89314639A patent/AR243385A1/es active
- 1989-08-11 DK DK394889A patent/DK394889A/da not_active Application Discontinuation
- 1989-08-11 EP EP89202080A patent/EP0354628B1/de not_active Revoked
- 1989-08-11 US US07/392,781 patent/US5254340A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE68914362T2 (de) | 1994-10-20 |
| AR243385A1 (es) | 1993-08-31 |
| CA1334388C (en) | 1995-02-14 |
| EP0354628B1 (de) | 1994-04-06 |
| DE68914362D1 (de) | 1994-05-11 |
| JPH0725697B2 (ja) | 1995-03-22 |
| DK394889A (da) | 1990-02-13 |
| ATE103816T1 (de) | 1994-04-15 |
| ES2055010T3 (es) | 1994-08-16 |
| JPH02152930A (ja) | 1990-06-12 |
| EP0354628A1 (de) | 1990-02-14 |
| US5254340A (en) | 1993-10-19 |
| DK394889D0 (da) | 1989-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60218998T2 (de) | Auf Bläschen basierender Impfstoff gegen Chlamydia | |
| DE69736709T2 (de) | Vielwertige dtp-polio-impfstoffe | |
| DE69735191T2 (de) | Verfahren zur Herstellung multivalenter Impfstoffe | |
| Hawgood | Albert Calmette (1863–1933) and Camille Guerin (1872–1961): the C and G of BCG vaccine | |
| DE60038099T2 (de) | Neisseria impfstoffzusammensetzungen und methoden | |
| NL8802007A (nl) | Vaccin, geschikt voor de profylaxe respectievelijk de bestrijding van de door haemophilus pleuropneumoniae teweeggebrachte ziekte bij varkens alsmede werkwijze voor het winnen van extracellulair eiwitachtig materiaal van haemophilus pleuropneumonie, geschikt voor toepassing in dergelijke vaccins. | |
| McIntosh et al. | Recovery of an extremely proteolytic form of Serratia liquefaciens as a pathogen of Atlantic salmon, Salmo solar, in Scotland | |
| US5855894A (en) | Pasteurella haemolytica type A-1 bacterin-toxoid vaccine | |
| DE69531186T2 (de) | Antibordetella azellulärer Impfstoff | |
| HUP0401077A2 (hu) | Mycoplasma bovis fertőzési modell, valamint eljárások M. bovis bejuttatására és tüdőgyulladásos tüdőléziók indukálására | |
| DE69838948T2 (de) | Epitopen eines extrazellulären antigens | |
| DE69333402T2 (de) | Impfstoff beinhaltend bacterin und toxoid aus pasteurella haemolytica typ a-1 | |
| DE60033291T2 (de) | Multi-komponenten impfstoff zum schutz vor krankheiten die durch haemophilus influenza und moxarella catarrhalis ausgelöst werden | |
| Rioux et al. | Evaluation of the protective efficacy of Actinohacillus pleuropneumoniae serotype 1 detoxified lipopolysaccharides or O-polysaccharide-protein conjugate in pigs | |
| DE69130953T2 (de) | Immunverstärkung von impfstoffen, besonders von impfstoffen gegen schweinepleuropneumonie | |
| US5750118A (en) | Vaccine method against swine dysentery | |
| Barber et al. | Discussion on swine erysipelas infection, Erysipelothrix rhusiopathiae, in man and animals. | |
| Johnson et al. | Intracerebral infection of mice with ovine strains of Chlamydia psittaci: an animal screening test for the assay of vaccines | |
| Cox | Some recent advances and current problems in the field of rickettsial diseases: Howard Taylor Ricketts Award Lecture 1951 | |
| RU2135196C1 (ru) | Способ иммунопрофилактики экспериментальной лепрозной инфекции | |
| Wark et al. | Laboratory evaluation of a living attenuated vaccine against bluetongue type 20 virus | |
| Girard | Evaluafion of the protective efficacy of ActinobacitItcs pleuropneumoniae serotype detoxined lipopo1ysaccharides or O-polysaccharide-protein | |
| Rappaport | Investigation of'Escherichia coli'Enterotoxins | |
| Brown | DNA Technology and Vaccines | |
| Kang | Studies on protective immunity against Bordetella bronchiseptica infection. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1B | A search report has been drawn up | ||
| BV | The patent application has lapsed |